ADRM1 and ovarian carcinoma: The initial study of RA190 demonstrated its potential as a cytotoxic chemotherapeutic agent based on therapeutic activity against ovarian cancer xenograft in immunocompromised mice [14], consistent with a role for RPN13 in ovarian cancer cell proliferation, migration and survival [16].